Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

Aclaris Therapeutics Inc (ACRS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Aclaris Therapeutics Inc's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.550 -0.130    -7.74%
29/07 - Closed. Currency in USD
After Hours
1.860
+0.310
+20.000%
0:59:52 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 7,271,080
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.540 - 1.710
Aclaris Therapeutics Inc 1.550 -0.130 -7.74%

Aclaris Therapeutics Inc Company Profile

 
Get an in-depth profile of Aclaris Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

63

Equity Type

ORD

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Contact Information

Address 701 Lee Road Suite 103
Wayne, 19087
United States
Phone 484 324 7933
Fax -

Top Executives

Name Age Since Title
Anand Mehra 48 2014 Independent Director
James J. Leyden 83 - Member of Advisory Board
Mark Bradshaw 71 - Member of Advisory Board
Klaus PJ Theobald 68 - Member of Advisory Board
Andrew Newman Schiff 59 2017 Independent Director
Kenneth Beer - - Member of Advisory Board
William D. Humphries 58 2016 Independent Director
Pearl E. Grimes - - Member of Advisory Board
Leslie Baumann - - Member of Advisory Board
Guy F. Webster - - Member of Advisory Board
Christopher P. Molineaux 58 2014 Lead Independent Director
Andrew L. Ondo - - Member of Advisory Board
Michael Elliott Weinblatt - 2020 Member of the Scientific Advisory Board
Marco Colonna - 2020 Member of the Scientific Advisory Board
Maxine Gowen 66 2019 Independent Director
Philip J. Mease - 2021 Member of Scientific Advisory Board
James G. Krueger - 2020 Member of the Scientific Advisory Board
Vincent J. Milano 60 2020 Independent Director
Stanley B. Cohen - 2020 Member of the Scientific Advisory Board
Zuzana Diamant - 2025 Member of Scientific Advisory Board
Marianne Mann - 2025 Member of Scientific Advisory Board
Neal S. Walker 55 2012 Co-Founder, CEO & Chairman
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ACRS Comments

Write your thoughts about Aclaris Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email